Royalty Pharma has demonstrated a consistent pattern of delivering earnings above analyst expectations across four straight quarters, but negative price momentum and a risk/reward profile tilted against new buyers suggest the stock's near-term opportunity has narrowed significantly.
Thesis pillars
- Consistent Earnings Beat Streak↑Improving
- Piotroski Financial Strength→Stable
- Analyst Sentiment And Coverage↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 11, 2026· older than 90 days
Royalty Pharma plc (RPRX) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $66.40, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (1.9% away).
Royalty Pharma acquires biopharmaceutical royalties, collecting payments based on top-line sales of more than 35 marketed therapies including Vertex's cystic fibrosis franchise, GSK's Trelegy, and Biogen's Tysabri. The company generated $3.3 billion in Portfolio Receipts in... Read more
Hold if already holding. Not a fresh buy at $66.40, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (1.9% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.1/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: speculative.
About Royalty Pharma plc
About Royalty Pharma plc
Royalty Pharma generated $3.3 billion in Portfolio Receipts in 2025 — consisting of $3,127 million in Royalty Receipts plus $128 million in milestones — across royalties on more than 35 commercialized biopharmaceutical therapies. The company's largest royalty, on Vertex's cystic fibrosis franchise, produced $917 million in 2025 Portfolio Receipts; 16 therapies in the portfolio each generated end-market sales exceeding $1 billion in 2025, including seven with end-market sales above $3 billion. Royalty Pharma deployed $2.6 billion in capital in 2025 to acquire additional royalties and milestones.
Royalty Pharma earns income as biopharmaceutical companies sell products on which it holds contractual royalty rights, structured as a percentage of top-line net sales ranging from low-single-digit rates to tiered mid-teen rates depending on volume thresholds. Royalties are collected from marketers including Vertex, GSK (Trelegy, $332 million in 2025 Portfolio Receipts), Biogen (Tysabri and Spinraza), Roche (Evrysdi), Pfizer and Astellas (Xtandi), and Johnson and Johnson (Tremfya and Erleada). The company bears no manufacturing, R&D, or commercial costs for these therapies. Portfolio growth comes from deploying capital to acquire new royalties — the company estimates a 48% market share of all biopharmaceutical royalty transactions by value from 2020 through 2025, versus approximately 14% for its nearest competitor. As of December 31, 2025, total outstanding principal on senior unsecured notes and term loans was $9.2 billion, with up to $1.8 billion in revolving credit available.
Show full overview
The cystic fibrosis franchise carries a material contractual dispute: Royalty Pharma believes deuterated ivacaftor (deutivacaftor) in Alyftrek is royalty-bearing, yielding a blended royalty of approximately 8%; Vertex has publicly stated it believes deutivacaftor is not royalty-bearing, yielding a blended royalty of approximately 4% on Alyftrek. Patent applications covering Trikafta are expected to provide exclusivity through 2037, with the franchise overall estimated through 2039-2041 — meaning the single largest Portfolio Receipts contributor faces both potential contractual revenue shortfall and structural decline over the following decade if generics enter.
See also: Healthcare · Biotechnology
From Royalty Pharma plc's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Oct 29, 2026Recent Developments — Royalty Pharma plc
Latest news
- NEWS Should You Buy Royalty Pharma Stock Before Nov. 4? - The Motley Fool — The Motley Fool Oct 29, 2026 neutral
- NEWS Should You Buy Royalty Pharma Stock Before Nov. 4? - Yahoo Finance — Yahoo Finance Oct 29, 2026 neutral
- NEWS Royalty Pharma (Nasdaq:RPRX) - Stock Analysis - Simply Wall St — Simply Wall St Oct 29, 2026 neutral
- NEWS Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Sterling Capital Management LLC Sells 39,687 Shares of Royalty Pharma PLC $RPRX - MarketBeat — MarketBeat Oct 27, 2026 neutral
Latest item Oct 29, 2026 · Generated 2026-11-04T12:04:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductVertex cystic fibrosis franchise10-K Item 1: 'Our largest marketed royalty in 2025 was on Vertex's cystic fibrosis franchise'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $66.40, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (1.9% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $56.88 reached (−14.3%), stop $63.60 (−4.4%), A.R:R -1.0:1. Score 5.1/10, moderate confidence.
Analyst target $56.88 reached (−14.3% from $66.40); no take-profit level is published. Analyst target $56.88 reached (−14.3%), stop $63.60 (−4.4%), A.R:R -1.0:1. Stop-loss: $63.60.
Analyst target reached - limited upside remaining; Near 52-week high (1.9% away); Expensive valuation.
Royalty Pharma plc trades at a P/E of 35.3 (forward 11.4). TrendMatrix value score: 3.9/10. Verdict: Hold.
14 analysts rate RPRX, with a consensus score of 4.2/5. 8 analysts publish price targets averaging $65.
What does Royalty Pharma plc do?Royalty Pharma acquires biopharmaceutical royalties, collecting payments based on top-line sales of more than 35...
Royalty Pharma acquires biopharmaceutical royalties, collecting payments based on top-line sales of more than 35 marketed therapies including Vertex's cystic fibrosis franchise, GSK's Trelegy, and Biogen's Tysabri. The company generated $3.3 billion in Portfolio Receipts in 2025, deploying $2.6 billion to acquire new royalties.